

REMARKS

Claims 34-51, as amended, and new claims 52-54 are pending in this application for the Examiner's review and consideration. Claim 41 has been amended to correct antecedent basis. New claims 52-54, depending from claim 34, recite features of the apparatus in preferred embodiments, support for which is found in the specification, e.g., paragraphs [0020] to [0024] and [0092] to [0094] of the published application. Claims 1-33 have been cancelled without prejudice. Applicant reserves the right to present the cancelled subject matter in a divisional application. As no new matter is introduced by any one of these changes and additions, their entry at this time is warranted.


In response to the restriction requirement, Applicant elects the Group II invention, including claims 34-51, drawn to a method for sustained transdermal delivery of a therapeutic or immunogenic agent. As new claims 52-54 depend from claim 34 reciting preferred embodiments of this method, they should also be examined at this time.

In view of the art that has been cited, it is believed that the application is now in condition for allowance.

Respectfully submitted,

Date

11/2/10



Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP

Customer No. 28765

212-294-3311